+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tumor (Cancer) Profiling Market by Technology and Geography - Forecast and Analysis 2020-2024

  • PDF Icon

    Report

  • 162 Pages
  • November 2019
  • Region: Global
  • TechNavio
  • ID: 4860958
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Tumor (Cancer) Profiling Market: About this market
The tumor (cancer) profiling market analysis considers sales from immunoassays, next-generation sequencing, polymerase chain reaction, and in-situ hybridization technologies. Our study also finds the sales of tumor (cancer) profiling in Asia, Europe, North America, and ROW. In 2019, the immunoassays segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as precise treatment decisions will play a significant role in the immunoassays segment to maintain its market position. Also, our global tumor (cancer) profiling market report looks at factors such as increasing incidences of cancer, low cost of genetic sequencing, and increasing awareness about tumor profiling. However, high cost of biomarkers development, lack of skilled professionals, and concerns related to variability in accuracy and precision in genomic analysis may hamper the growth of the tumor (cancer) profiling industry over the forecast period.

Global Tumor (Cancer) Profiling Market: Overview

Increasing awareness about tumor profiling
Various government and private organizations and companies are creating awareness about the significance of tumor profiling, its diagnosis and personalized treatment of cancer. They are releasing educational videos and using email campaigns to educate both patients and physicians about the availability of effective and personalized treatment options and the need for genetic testing for timely diagnosis of cancer. Thus, increasing awareness about tumor profiling will lead to the expansion of the global tumor (cancer) profiling market at a CAGR of over 10% during the forecast period.

The growing importance of genomics in therapeutics
The importance of genomics technologies, such as microarray and genome editing in therapeutics, helped shape the future of therapeutics in pharmaceutical industries. Genomic profiling is done through polymerase chain reaction (PCR), ligase chain reaction (LCR), and transcription-mediated technologies. The rising focus of researchers on developing genomic databases, such as GenBank and the European Molecular Biology Laboratory (EMBL), has brought significant changes in the healthcare system by accelerating research progress in personalized medicines, drug development, clinical research, and gene therapies. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global tumor (cancer) profiling market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading tumor (cancer) profiling manufacturers, that include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Co., bioMérieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

Also, the tumor (cancer) profiling market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Table of Contents

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value Chain Analysis

PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market Outlook

PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TECHNOLOGY
  • Market segmentation by technology
  • Comparison by technology
  • Immunoassays - Market size and forecast 2019-2024
  • Next generation sequencing - Market size and forecast 2019-2024
  • Polymerase chain reaction - Market size and forecast 2019-2024
  • In-situ hybridization - Market size and forecast 2019-2024
  • Market opportunity by technology

PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS
  • Increasing cancer research and funding
  • Increasing adoption of personalized medicine
  • Growing importance of genomics in therapeutics

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton, Dickinson and Co.
  • bioMérieux SA
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

List of Exhibits
Exhibit 01: Vendor: Key offerings
Exhibit 02: Global healthcare technology market
Exhibit 03: Segments of global healthcare technology market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2019
Exhibit 18: Technology - Market share 2019-2024 (%)
Exhibit 19: Comparison by technology
Exhibit 20: Immunoassays - Market size and forecast 2019-2024 ($ millions)
Exhibit 21: Immunoassays - Year-over-year growth 2020-2024 (%)
Exhibit 22: Next generation sequencing - Market size and forecast 2019-2024 ($ millions)
Exhibit 23: Next generation sequencing - Year-over-year growth 2020-2024 (%)
Exhibit 24: Polymerase chain reaction - Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Polymerase chain reaction - Year-over-year growth 2020-2024 (%)
Exhibit 26: In-situ hybridization - Market size and forecast 2019-2024 ($ millions)
Exhibit 27: In-situ hybridization - Year-over-year growth 2020-2024 (%)
Exhibit 28: Market opportunity by technology
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2019-2024 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2019-2024 ($ millions)
Exhibit 33: North America - Year-over-year growth 2020-2024 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2019-2024 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2020-2024 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2019-2024 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2020-2024 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2019-2024 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2020-2024 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Abbott Laboratories - Vendor overview
Exhibit 53: Abbott Laboratories - Business segments
Exhibit 54: Abbott Laboratories - Organizational developments
Exhibit 55: Abbott Laboratories - Geographic focus
Exhibit 56: Abbott Laboratories - Segment focus
Exhibit 57: Abbott Laboratories - Key offerings
Exhibit 58: Abbott Laboratories - Key customers
Exhibit 59: Agilent Technologies Inc. - Vendor overview
Exhibit 60: Agilent Technologies Inc. - Product segments
Exhibit 61: Agilent Technologies Inc. - Organizational developments
Exhibit 62: Agilent Technologies Inc. - Geographic focus
Exhibit 63: Agilent Technologies Inc. - Segment focus
Exhibit 64: Agilent Technologies Inc. - Key offerings
Exhibit 65: Agilent Technologies Inc. - Key customers
Exhibit 66: Becton, Dickinson and Co. - Vendor overview
Exhibit 67: Becton, Dickinson and Co. - Business segments
Exhibit 68: Becton, Dickinson and Co. - Organizational developments
Exhibit 69: Becton, Dickinson and Co. - Geographic focus
Exhibit 70: Becton, Dickinson and Co. - Segment focus
Exhibit 71: Becton, Dickinson and Co. - Key offerings
Exhibit 72: Becton, Dickinson and Co. - Key customers
Exhibit 73: bioMérieux SA - Vendor overview
Exhibit 74: bioMérieux SA - Product segments
Exhibit 75: bioMérieux SA - Organizational developments
Exhibit 76: bioMérieux SA - Geographic focus
Exhibit 77: bioMérieux SA - Key offerings
Exhibit 78: bioMérieux SA - Key customers
Exhibit 79: Bio-Rad Laboratories Inc. - Vendor overview
Exhibit 80: Bio-Rad Laboratories Inc. - Business segments
Exhibit 81: Bio-Rad Laboratories Inc. - Organizational developments
Exhibit 82: Bio-Rad Laboratories Inc. - Geographic focus
Exhibit 83: Bio-Rad Laboratories Inc. - Segment focus
Exhibit 84: Bio-Rad Laboratories Inc. - Key offerings
Exhibit 85: Bio-Rad Laboratories Inc. - Key customers
Exhibit 86: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 87: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 88: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 89: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 90: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 91: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 92: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 93: Illumina Inc. - Vendor overview
Exhibit 94: Illumina Inc. - Business segments
Exhibit 95: Illumina Inc. - Organizational developments
Exhibit 96: Illumina Inc. - Geographic focus
Exhibit 97: Illumina Inc. - Segment focus
Exhibit 98: Illumina Inc. - Key offerings
Exhibit 99: Illumina Inc. - Key customers
Exhibit 100: QIAGEN NV - Vendor overview
Exhibit 101: QIAGEN NV - Product segments
Exhibit 102: QIAGEN NV - Organizational developments
Exhibit 103: QIAGEN NV - Geographic focus
Exhibit 104: QIAGEN NV - Segment focus
Exhibit 105: QIAGEN NV - Key offerings
Exhibit 106: QIAGEN NV - Key customers
Exhibit 107: Siemens Healthineers AG - Vendor overview
Exhibit 108: Siemens Healthineers AG - Business segments
Exhibit 109: Siemens Healthineers AG - Organizational developments
Exhibit 110: Siemens Healthineers AG - Geographic focus
Exhibit 111: Siemens Healthineers AG - Segment focus
Exhibit 112: Siemens Healthineers AG - Key offerings
Exhibit 113: Siemens Healthineers AG - Key customers
Exhibit 114: Thermo Fisher Scientific Inc. - Vendor overview
Exhibit 115: Thermo Fisher Scientific Inc. - Business segments
Exhibit 116: Thermo Fisher Scientific Inc. - Organizational developments
Exhibit 117: Thermo Fisher Scientific Inc. - Geographic focus
Exhibit 118: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 119: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 120: Thermo Fisher Scientific Inc. - Key customers
Exhibit 121: Validation techniques employed for market sizing
Exhibit 122: Definition of market positioning of vendors

Executive Summary

The following companies as the key players in the global tumor (cancer) profiling market: Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Co., bioMérieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing importance of genomics in therapeutics.”

According to the report, one of the major drivers for this market is the increasing awareness about tumor profiling.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of biomarkers development.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton
  • Dickinson and Co.
  • bioMérieux SA
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.